RE: Mycobacterium tuberculosis Beijing type mutation frequency: In response

Emerging Infectious Diseases

Volumn 19, Issue 3, 2013, Pages 522-523

  de Steenwinkel, Jurriaan E M ^a   van Soolingen, Dick ^b,c   Bakker Woudenberg, Irma A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; COLONY FORMING UNIT; GENOTYPE; LETTER; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84874285813     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1903.121849     Document Type: Letter

References (4)

1. Werngren J. Mycobacterium tuberculosis Beijing type mutation frequency [letter]. Emerg Infect Dis. 2013:19:522.
2. Werngren J, Hoffner SE. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J Clin Microbiol. 2003;41:1520-4. http://dx.doi.org/10.11 28/JCM.41.4.1520-1524.2003
3. Bergval IL, Schuitema AR, Klatser PR, Anthony RM. Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance. J Antimicrob Chemother. 2009;64:515-23. http://dx.doi.org/10.1093/jac/dkp237
4. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard M24-A2. 2nd ed. Wayne (PA): The Institute; 2011.